Search

Search Constraints

You searched for: Author/Creator Musacchio, Lucia

Search Results

1. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. (20th October 2022)

2. 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22. (20th October 2022)

3. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician's choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). (20th October 2022)

4. A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. Issue 9 (21st March 2022)

5. Adnexal masses in pregnancy: an updated review on diagnosis and treatment. Issue 1 (February 2021)

6. Advanced and recurrent endometrial cancer: State of the art and future perspectives. (December 2022)

7. Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?. Issue 6 (3rd June 2021)

8. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. Issue 3 (March 2023)

9. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. Issue 7 (14th May 2021)

10. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. Issue 7 (July 2021)